Insider Transactions in Q2 2023 at Regeneron Pharmaceuticals, Inc. (REGN)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 01
2023
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
250
-1.2%
|
$184,000
$736.0 P/Share
|
|
Jun 01
2023
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.06%
|
$73,400
$734.44 P/Share
|
|
May 15
2023
|
Leonard S Schleifer Bd. Co-Chair, President & CEO |
BUY
Bona fide gift
|
Indirect |
53,807
+45.3%
|
-
|
|
May 15
2023
|
Leonard S Schleifer Bd. Co-Chair, President & CEO |
SELL
Bona fide gift
|
Indirect |
53,807
-100.0%
|
-
|
|
May 09
2023
|
Andrew J Murphy EVP Research |
SELL
Bona fide gift
|
Direct |
1,326
-2.18%
|
-
|
|
May 01
2023
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.08%
|
$80,500
$805.46 P/Share
|
|
Apr 21
2023
|
Michael S Brown Director |
SELL
Open market or private sale
|
Direct |
3,070
-71.11%
|
$2,449,860
$798.42 P/Share
|
|
Apr 21
2023
|
Michael S Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,070
+41.56%
|
$1,596,400
$520.01 P/Share
|
|
Apr 03
2023
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
1,100
-5.02%
|
$899,800
$818.8 P/Share
|
|
Apr 03
2023
|
Marion Mc Court EVP Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
1,100
+4.78%
|
$409,200
$372.46 P/Share
|
|
Apr 03
2023
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.07%
|
$81,900
$819.99 P/Share
|
|
Apr 03
2023
|
P Roy Vagelos Director |
SELL
Bona fide gift
|
Indirect |
259
-0.21%
|
-
|